Wearables To Bolster Rapid Influenza Diagnostic Tests Market At A CAGR Of 8.7%

New York, United States, 2022-May-23 — /EPR Network/ —

The global Rapid Influenza Diagnostic Tests Market is expected to witness a CAGR of 8.7% and reach US$ 2 Bn by the year 2031. With the way in which healthcare data gets accumulated these days (which could be inclusive of medical IoT solutions, DICOM files, and patient records), ultra-modern platforms like data fabrics are in the offing, so that distributed and structured data could be well-managed. This would be healthcare industry’s situation in the upcoming period.

As per Persistence Market Research’s latest revised industry analysis, the global rapid influenza diagnostic tests market is expected to witness high growth during the forecast period. The market is expected to top US$ 2 Bn by 2031, which reflects a CAGR of around 8.7% for the decade.

Influenza is recognized as a major source of illness and mortality in humans, prompting the development and implementation of diagnostics aimed at decreasing the health and economic consequences. Influenza causes serious illness or death, primarily in high-risk people.

With the start of the flu season comes an increase in antibiotic use, elevating the danger of antibiotic resistance in the body. The speedy turn-around times of devices used at point-of-care aid in the preparation of a targeted and successful treatment plan based on test results. Rapid influenza diagnostic tests have a short turnaround time, with some offering results in under 15 minutes. As a result, adoption of rapid influenza diagnostic tests helps prevent over-prescription of antibiotics as well as avoid the core cause of bacterial resistance and its negative consequences.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/31040

The current COVID-19 pandemic has also boosted demand for rapid influenza diagnostic tests. When compared to influenza, COVID-19 has a similar illness presentation – both viruses induce respiratory problems. Furthermore, both are spread via touch, droplets, and fomites. COVID-19 patients have been misdiagnosed with influenza in the past, which has increased demand for virus rapid detection kits.

Emergence of smartphone-based disease screening has increased market revenue. The Human Genome Project and breakthroughs in molecular and biomedical technology have led to the creation of a plethora of assays and technologies useful for the diagnosis and monitoring of influenza infections.

These new technologies, which are based on genomic (PCR-based) and proteomic (microarray-based detection) techniques, aid in the discovery of novel influenza viruses. They also allow for improved surveillance and rapid detection of infectious diseases, which presents a good business opportunity for market players.

Company Profiles:

• Thermo Fisher Scientific
• Hologic
• Quidel Corporation
• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Becton Dickinson and Company
• Danaher Corporation
• Meridian Bioscience
• bioMérieux SA
• Luminex Corporation
• Siemens Healthineers AG
• GenMark Diagnostics
• Sekisui Diagnostics
• LLC altona Diagnostics GmbH
• SA Scientific
• ELITech Group

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/31040

Key Takeaways from Market Study

• By principle, immunochromatographic assays are set hold high share of 66.8% in 2021, expanding at 6.1% CAGR over the forecast period.
• By test type, influenza A+B test is expected to hold 79% market share, and is expected to continue growing at similar trend due to its benefits such as simple to use and rapid diagnosis.
• By sample, the nasopharyngeal swab segment is expected to 31% market share, and nasopharyngeal aspirate is the second-leading segment, which accounts for 27.5%.
• By end user, office-based settings account for nearly 22.5% market share.
• By region, North America held 36.6% of the global market share in 2021.

“Rising demand for rapid disease diagnosis, increasing influenza prevalence, and increased research for diagnostic technologies are expected to provide growth opportunities for market players,” says an analyst of Persistence Market Research.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/31040

Market Competition

Leading market players are focusing on product approvals and launches as a key growth strategy for global expansion, thereby enhancing their market presence. They are also emphasizing on entering into strategic partnerships with local suppliers and distributors to expand product reach.

• In March 2021, Abbott received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its AlinityTM m Resp-4-Plex molecular assay, which can identify and discriminate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) all in one test. This test has received CE certification and is available in countries other than the United States.
• In February 2020, the FDA granted Quidel an Emergency Use Authorization (EUA) to market its Sofia® 2 Flu + SARS Antigen FIA for the rapid, simultaneous qualitative identification, and characterization of nucleocapsid protein antigens from SARS-CoV-2, influenza A, and influenza B in direct nasopharyngeal (NP) and nasal (NS) swab samples from persons suspected of respiratory viral infection consistent with COVID-19.
• In August 2017, Meridian Bioscience, Inc. announced the expansion of its ImmunoCard STAT!® product line with the addition of ImmunoCard STAT! FLU A&B.

CAR T-Cell Therapy Market- https://www.persistencemarketresearch.com/market-research/car-t-cell-therapy-market.asp

Cell Culture Media Market- https://www.persistencemarketresearch.com/market-research/cell-culture-media-market.asp

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com